Journal article

Oral Cannabidiol does not Alter the Subjective, Reinforcing or Cardiovascular Effects of Smoked Cannabis

Margaret Haney, Robert J Malcolm, Sharma Babalonis, Paul A Nuzzo, Ziva D Cooper, Gillinder Bedi, Kevin M Gray, Aimee McRae-Clarke, Michelle R Lofwall, Steven Sparenborg, Sharon L Walsh

Neuropsychopharmacology | NATURE PUBLISHING GROUP | Published : 2016

University of Melbourne Researchers


Awarded by US National Institute on Drug Abuse

Funding Acknowledgements

This research was supported by the US National Institute on Drug Abuse (DA009236, U10DA013727, U10DA13732). We also thank NIDA for supplying the cannabis to conduct this study, and Dr Hari Singh, PhD at NIDA for facilitating the analysis of plasma CBD concentrations by Dr David Moody, PhD at University of Utah (NIDA contract #NO1DA-14-7788). Many thanks to Dr Richard W Foltin (CUMC) and Dr Thomas H Kelly (UK) for their support in conducting this study, and to the expert contributions of Dr Adam Bisaga, Olivia Derella (CUMC), Dr Samy Claude Elayi, Tori Votaw, and Cleeve Emurian (UK). This research was funded by NIDA. Dr Haney has received research support from Aelis Farma and Lifeloc Technologies, and along with Dr Cooper, has received research support from investigator-initiated studies from Insys Therapeutics. Dr Cooper serves as a consultant to KannaLife Sciences and PharmaCann, LLC. Dr McRae-Clark has received research support from Forest Pharmaceuticals (medication only). Dr Gray has received research funding from Supernus Pharmaceuticals and Merck, for unrelated research.